comparemela.com

Latest Breaking News On - Michael castagna - Page 2 : comparemela.com

MannKind Repays Certain Debt Obligations

Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common.

Christie-iacangelo
Michael-castagna
Rose-alinaya
Exchange-commission
Amann-group
Midcap-financial-trust-the-loan-agreement
Mannkind-corporation
Facebook
Linkedin
Mannkind-corporation-nasdaq
Corporate-communications
Midcap-financial

MannKind Announces CFO Transition

MannKind Announces CFO Transition
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Loyola-marymount-university
California
United-states
Westlake-village
Christopher-prentiss
Michael-castagna
Stevenb-binder
Steve-binder
Intermune-inc
Linkedin
Supernus-pharmaceuticals-inc
Exchange-commission

MannKind Announces CFO Transition

Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through Decem.

Loyola-marymount-university
California
United-states
Westlake-village
Steve-binder
Christopher-prentiss
Stevenb-binder
Michael-castagna
Adamas-pharmaceuticals-inc
Intermune-inc
Adarx-pharmaceuticals-inc
Linkedin

MannKind caps off record year with Q4 earnings beat | Pacific Coast Business Times

MannKind employees including CEO Michael Castagna, center, ring the opening bell of the Nasdaq on May 23. (courtesy photo) Westlake Village-based MannKind Corporation capped off a record year with a fourth quarter to remember, beating analysts' estimates and setting up for a brighter future. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary

Michael-castagna
Westlake-mannkind-corporation
Westlake-village-based-mannkind-corporation

Wedbush Weighs in on MannKind Co.'s Q2 2024 Earnings (NASDAQ:MNKD)

MannKind Co. (NASDAQ:MNKD – Free Report) – Analysts at Wedbush issued their Q2 2024 earnings estimates for shares of MannKind in a research report issued to clients and investors on Wednesday, February 28th. Wedbush analyst A. Argyrides forecasts that the biopharmaceutical company will post earnings of $0.02 per share for the quarter. Wedbush currently has […]

United-states
Michael-castagna
Mannkind-corporation
Cantor-fitzgerald
Group-plc
Mannkind-co
Capital-partners
Barclays-plc
Securities-exchange-commission
Nasdaq
Virtu-financial
Pricet-rowe-associates-inc

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.